Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrike Lorch

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Clinical Pharmacology|June 17, 2024
The safety of early phase clinical trials: Bridging the gap between governance and practiceUlrike Lorch, Charles Vincent
European Journal of Clinical Pharmacology|December 21, 2018
Practical risk management in early phase clinical trialsSimon Coates, Jörg Täubel, Ulrike Lorch
BMC Medical Research Methodology|July 2, 2014
Three steps to writing adaptive study protocols in the early phase clinical development of new medicinesUlrike Lorch, Martin O'Kane, Jorg Taubel
Biomed Research International|October 29, 2015
The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation StudyGeorg Ferber, Ulrike Lorch, Jörg Täubel
Cureus|September 29, 2023
Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled TrialsVishal Aggarwal, Jorg Taubel, Ulrike Lorch, et al.
Journal of Atherosclerosis and Thrombosis|December 22, 2015
Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese SubjectsJorg Taubel, Mark Sumeray, Ulrike Lorch, et al.
Cureus|August 10, 2023
The Reliability of Auto-Injectors in Clinical Use: A Systematic ReviewPetr Dostal, Jorg Taubel, Ulrike Lorch, et al.
Frontiers in Immunology|December 30, 2022
A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activationWeston L Daniel, Ulrike Lorch, Scott Mix, et al.
Clinical Pharmacology in Drug Development|August 5, 2020
Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese VolunteersUlrike Lorch, Tomasz Pierscionek, Anne Freier, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development ProgramsSimon Coates, Oliver Pohl, Jean-Pierre Gotteland, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|June 17, 2024
The safety of early phase clinical trials: Bridging the gap between governance and practiceUlrike Lorch, Charles Vincent
European Journal of Clinical Pharmacology|December 21, 2018
Practical risk management in early phase clinical trialsSimon Coates, Jörg Täubel, Ulrike Lorch
BMC Medical Research Methodology|July 2, 2014
Three steps to writing adaptive study protocols in the early phase clinical development of new medicinesUlrike Lorch, Martin O'Kane, Jorg Taubel
Biomed Research International|October 29, 2015
The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation StudyGeorg Ferber, Ulrike Lorch, Jörg Täubel
Cureus|September 29, 2023
Blinding Is Seeing: A Single-Centre Study Into the Viability of Auto-Injectors for Blinded-Drug Administration in Randomised Controlled TrialsVishal Aggarwal, Jorg Taubel, Ulrike Lorch, et al.
Journal of Atherosclerosis and Thrombosis|December 22, 2015
Pharmacokinetics and Pharmacodynamics of Lomitapide in Japanese SubjectsJorg Taubel, Mark Sumeray, Ulrike Lorch, et al.
Cureus|August 10, 2023
The Reliability of Auto-Injectors in Clinical Use: A Systematic ReviewPetr Dostal, Jorg Taubel, Ulrike Lorch, et al.
Frontiers in Immunology|December 30, 2022
A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activationWeston L Daniel, Ulrike Lorch, Scott Mix, et al.
Clinical Pharmacology in Drug Development|August 5, 2020
Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese VolunteersUlrike Lorch, Tomasz Pierscionek, Anne Freier, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development ProgramsSimon Coates, Oliver Pohl, Jean-Pierre Gotteland, et al.
Pageof 5